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OBJECTIVE: To evaluate the correlation between transforming growth factor beta (TGF-b1) expression and
prognosis in prostate cancer.
PATIENTS AND METHODS: TGF-b1 expression levels were analyzed using the quantitative real-time polymerase
chain reaction to amplify RNA that had been isolated from fresh-frozen malignant and benign tissue specimens
collected from 89 patients who had clinically localized prostate cancer and had been treated with radical
prostatectomy. The control group consisted of 11 patients with benign prostate hyperplasia. The expression levels of
TGF-b1 were compared between the groups in terms of Gleason scores, pathological staging, and prostate-specific
antigen serum levels.
RESULTS: In the majority of the tumor samples, TGF-b1 was underexpressed 67.0% of PCa patients. The same
expression pattern was identified in benign tissues of patients with prostate cancer. Although most cases exhibited
underexpression of TGF-b1, a higher expression level was found in patients with Gleason scores $7 when compared
to patients with Gleason scores ,7( p=0.002). Among the 26 cases of TGF-b1 overexpression, 92.3% had poor
prognostic features.
CONCLUSIONS: TGF-b1 was underexpressed in prostate cancers; however, higher expression was observed in tumors
with higher Gleason scores, which suggests that TGF-b1 expression may be a useful prognostic marker for prostate
cancer. Further studies of clinical specimens are needed to clarify the role of TGF-b1 in prostate carcinogenesis.
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INTRODUCTION
Prostate cancer (PCa) is the most common male malig-
nancy and is the second-highest cause of death in many
countries, including Brazil.
1 Pathological staging, Gleason
scores, and prostate-specific antigen (PSA) serum levels are
the most reliable prognostic factors; however, even when
combined, they do not perfectly identify patients who are at
risk of progression.
2 Therefore, research has been aimed at
identifying molecular markers that can predict PCa predis-
position and progression.
Transforming growth factor beta (TGF-b) is the proto-
typical member of a superfamily that includes more than 25
members, including inhibin, bone morphogenetic protein,
and Mu ¨llerian inhibiting substance. The TGF-b subfamily
contains five members named TGF-b1 through b5. TGF-b1,
-b2, and -b3 have been identified in mammals.
3,4 Although
TGF-b is a pleiotropic growth factor, it inhibits growth in
most cell types, especially cells of epithelial lineage. TGF-b
also inhibits prostatic epithelial cell proliferation and
induces apoptosis.
5,6 In addition to its numerous effects on
cell proliferation, phenotype, and differentiation,
7 TGF-b is
an important transcriptional regulator of extracellular
matrix components.
Malignant transformation is characterized by multiple
genetic mutations that confer a growth advantage to
transformed cells compared with benign cells. The devel-
opment of prostate cancer follows this paradigm. TGF-b
is involved in two critical events that are consistently
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1143associated with the conversion from a benign state to a
malignant state: 1) a reduction or loss of the sensitivity to
the inhibitory effects of TGF-b and 2) an increase in the
ability to elevate TGF-b expression levels, which in turn
promotes carcinogenesis by stimulating extracellular matrix
production, promoting angiogenesis, and inhibiting the host
immune system.
8
To evaluate whether the expression levels of TGF-b1i n
prostate cancer cells are associated with prognosis, as
predicted by the TGF-b elevation in carcinogenesis, we
investigated a putative correlation between TGF-b gene




This study was conducted using surgical specimens from
79 patients with clinically localized PCa who underwent
radical prostatectomy in our institution between 1993 and
2007; patients with a minimum follow-up of five years were
randomly selected from a frozen tumor tissue database
(Table 1). Benign tissue samples from an additional 10
patients with PCa who also underwent radical prostatect-
omy were included in this group. Patients who had
undergone other treatments for PCa were excluded. All of
the subjects provided their informed consent to participate
in the study and to allow their biological samples to be
genetically analyzed. Approval for the study was given by
the Institutional Board of Ethics (n˚0453/08).
We correlated the expression levels of the TGF-b1 genes
in each sample with the patient’s Gleason score, pathologic
stage according to the TNM 2002 staging system, and serum
PSA level (in ng/ml). For the analysis, the pathologic stage
was considered as an organ-confined (pT2) or non-organ-
confined (pT3) disease. The Gleason score was classified as
low grade (,7) or high grade ($7), and preoperative PSA
was used to identify patients at high ($10 ng/ml) or low
risk (,10 ng/ml) for disease recurrence. In addition, at a
mean follow-up time of 60 months, we analyzed the gene
expression levels in patients with biochemical recurrence,
which was defined as a PSA level .0.4 ng/ml.
The control group consisted of tissue specimens from 11
patients with benign prostate hyperplasia (BPH) who
presented with lower urinary tract symptoms and had an
interest in undergoing surgery (mean age 64¡6.0 years).
RNA Isolation and cDNA Synthesis
All of the tumor samples were obtained from surgical
specimens and immediately frozen in liquid nitrogen at
-170˚C. A mirror image slide of the frozen fragment was
stained with hematoxylin and eosin to verify that the tumor
represented at least 75% of the fragment in the cancer
patients and that no tumors were present in the control
patients with BPH.
Total RNA was isolated using the RNAaqueous Kit
(Applied Biosystems, CA, USA) according to the manufac-
turer’s instructions. The RNA concentration was deter-
mined by the ratio of the absorbance at 260 and 280 nm
using a NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, USA). cDNA was generated using the High
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). The reactions were incubated at 25˚C for
10 min, followed by 37˚C for 120 min and 85˚C for 5 min.
The cDNA was stored at -20˚C until use.
Quantitative Real-Time Polymerase Chain Reaction
and Gene Expression
The expression level of the TGF-b1 gene was analyzed using
quantitative real-time polymerase chain reaction (qRT-PCR)
with the ABI 7500 Fast system (Applied Biosystems). The
target sequences were amplified in a 10 ml reaction volume
containing 5 ml TaqMan Universal PCR Master Mix, 0.5 ml
TaqMan Gene Expression Assays (TGF-b Hs00852894_m1 and
B2M Hs99999907_m1), 1 mlc D N A ,a n d3 . 5ml DNase-free
water.Thepolymerasechainreaction(PCR)cyclingconditions
were 2 min at 50˚Ca n d1 0m i na t9 5˚C, followed by 40 cycles
of 15 seconds at 95˚Ca n d1m i na t6 0 ˚C. The TaqMan
endogenous control assay utilized b-2-microglobulin (B2M).
We used the DDCT method to calculate the relative
expression levels of the two target genes using the formula
DDCT = (CT target gene, PCa sample - CT endogenous
control, PCa sample) – (CT target gene, BPH sample - CT
endogenous control, BPH sample). The fold change in gene
expression was calculated as 2
-DDCT.
Statistical Analyses
Quantitative variables were expressed as median values,
interquartile ranges (Q1-Q3), and minimum and maximum
values. Qualitative variables were expressed as numbers and
percentages. We constructed a box plot for a descriptive
analysis of TGF-b expression according to pathologic stage,
Gleason score, and PSA level. We used the Mann-Whitney test
to compare categories. Statistical analyses were performed
using GraphPad Prism 3, and significance was set at p#0.05.
RESULTS
As shown in Figure 1, an analysis of the 79 patients with
PCa showed that TGF-b1 was underexpressed (median
6.07610
-1-fold) in malignant prostatic tissue as compared to
the BPH samples.
The TGF-b1 expression levels in relation to the Gleason
scores are shown in Table 2. The median TGF-b1 expression
levels were significantly higher (p=0.0065) among patients
with a Gleason score $7 (9.4610
-1-fold) compared with
those patients with a Gleason score ,7 (4.6610
-1-fold).
With regard to the pathologic stage, the expression of
TGF-b1 was similar (p=0.2514) between stage pT3 patients
(median 4.9610
-1-fold) and stage pT2 patients (median
6.6610
-1-fold). When the results were evaluated according
Table 1 - Age and clinical characteristics of 79 men who




Min - Max 41 - 79
PSA (ng/ml)
Mean 10.8
Min - Max 2.0 - 37.0
,10 n (%) 47 (59.5)
$10 n (%) 32 (40.5)
Stage
pT2 n (%) 38 (48)
pT3 n (%) 41 (52)
Gleason Score
,7 n (%) 32 (41.7)
$7 n (%) 46 (58.3)
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1144to preoperative PSA values, the median TGF-b1 expression
levels were also similar (p=0.5110) between patients with
PSA levels $10 ng/ml (6.7610
-1-fold) and patients with PSA
levels ,10 (5.5610
-1-fold).
We found an overexpression of TGF-b1 in 26 cases, of
which 21 (80.7%) had a Gleason score $7, 13 (50%) had a
PSA level $10 ng/ml, 12 (46%) were staged as pT3 and 9
(35%) had biochemical recurrence. Only 2 (7.7%) of the
patients with TGF-b1 overexpression exhibited no unfavor-
able prognostic factors.
We also evaluated the expression levels of TGF-b1i n
patients with biochemical recurrence (which wasdefined as a
PSA level above 0.4 ng/ml) at a mean follow-up period of 60
months. Median TGF-b1 expression levels were statistically




We performed a multivariate analysis, and the Gleason
score was the unique independent prognostic factor in our
series (p=0.022).
Additionally, we tested the expression of TGF-b1 in the
prostatic tissues from 10 patients with benign PCa and
found the same expression patterns as observed in the




malignant prostatic tissue as compared to BPH samples
(median 7610
-1-fold). Thus, we may assume that TGF-b
contributestothedevelopmentofprostatecancerbyactingas
an inhibitor of cell proliferation and an inducer of apopto-
sis.
8,9 Furthermore, we identified higher TGF-b expression
levels in tumors with higher Gleason scores, suggesting that
this gene may play a role in PCa progression and prognosis.
Soulitzis et al
10 also reported a decrease in TGF-b
expression in PCa. TGF-b is generally a growth inhibitor
of both benign prostatic epithelial cells
11 and prostate cancer
cells in vitro
12 and has been shown to inhibit proliferation
and induce apoptosis in prostatic epithelial cells.
8,13
Moreover, TGF-b stimulates the synthesis of collagen,
fibronectin, and integrins, and it inhibits matrix degradation
through the downregulation of proteinases such as collage-
nases, stromelysins, and plasminogen activators.
14 Pairedwith
its downregulation of proteinases, TGF-b upregulates protei-
nase inhibitors such as the following endogenous matrix
metalloproteinases (MMP) inhibitors: the tissue inhibitor of
metalloproteinase-1 (TIMP-1)
15 and plasminogen activator
inhibitor-1.
16 TGF-b also acts as a repressor of matrix
metalloproteinase expression through the TGF-b inhibitory
element (TIE), which is found in the 59-flanking region of
several genes in the MMP family, namely interstitial collage-
nase (MMP-1) and 92-kDa type IV collagenase (MMP-9).
17
Figure 1 - Quantitative expression of TGF-b1 messenger RNA in malignant prostatic tissue compared with BPH. Fold change in
expression was calculated using the 2-DDCT method.
Table 2 - Relative expression of the TGF-b1 gene in the
malignant prostatic tissues according to Gleason score,
pathologic stage, PSA level and biochemical recurrence.
Fold changes in gene expression were calculated using




,7 (n=32) 0.46 (0.02 - 6.20)
$7 (n=36) 0.93 (0.02 - 33.3)
p-value 0.006
Pathologic Stage
pT2 (n=37) 0.65 (0.02 - 33.3)
pT3 (n=40) 0.48 (0.04 - 18.9)
p-value 0.249
PSA Level
,10 (n=45) 0.55 (0.04 - 33.3)
$10 (n=33) 0.67 (0.02 - 14.3)
p-value 0.508
Biochemical Recurrence
Without (n=29) 0.60 (1.12 - 33.3)
With (n=28) 0.54 (0.04 - 18.9)
p-value 0.523
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1145Interestingly, a quantitative analysis revealed a positive
association between increased TGF-b1 mRNA levels and
elevated Gleason scores (p=0.002). Although controversial,
this finding is consistent with that of a previous study in which
TGF-b plasma levels were higher in men with PCa metastases
than in healthy men.
18 Shariat et al
19 also found a strong
correlation between elevated plasma TGF-b and prostate
cancer progression and the development of metastases in
patients with locally advanced disease. Faria et al
20 demon-
strated that among patients with PCa, the relative levels of
TGF-b1 mRNA increased during the late stages of the disease.
Some studies have suggested that decreased expression of
TGF-b is not entirely necessary, as some tumor cells might
escape the inhibitory effects of TGF-b through mutations
that could provide a growth advantage over their benign
counterparts. It has also been established that both TGF-b
receptors (TbR-I and TbR-II) are required for the proper
transduction of TGF-b signaling,
21 and prostate cancer cells
might reduce the expression or function of either TbR-I or
TbR-II to escape the growth-inhibiting effects of TGF-b. This
loss of sensitivity to TGF-b by its receptors could induce a
compensatory overexpression of TGF-b, thereby leading to
more aggressive phenotypes.
22
Research has suggested that whether TGF-b exerts a
tumor-suppressive or oncogenic effect is contextual and/or
depends upon the temporal stage of cellular transforma-
tion.
23 A recent study reported that the activation of TGF-b
signaling pathways might be responsible for mediating the
epithelial-mesenchymal transition (EMT), thereby enhan-
cing the invasiveness and survival of transformed cells.
24
Moreover, TGF-b can alter the host-tumor interaction, thus
facilitating tumor growth, promoting angiogenesis, and
inhibiting the host immune system.
9,25
Byexamining benigntissuesfromtheremoved prostatesof
patients with PCa who were treated by radical prostatect-
omy, we observed the same TGF-b expression pattern as in
malignant tissue. This result is interesting because it allows
us to propose the use of TGF-b as a tumor marker, there-
by overcoming the sampling error that commonly occurs
in conventional prostate biopsies; however, larger studies
should be conducted to further validate our findings.
In conclusion, we showed for the first time in clinical
specimens that decreased expression of TGF-b is a char-
acteristic of prostate cancer and may be related to cancer
initiation and promotion; the role of TGF-b as a regulator of
cell growth and apoptosis should be confirmed in a wider
series. On the other hand, TGF-b superexpression might be
related to tumor progression, as it is more highly expressed
in more aggressive tumors, and this finding could be
explained by mutations that confer resistance to TGF-b
receptors. This hypothesis also warrants further experi-
mental studies to analyze the potential of TGF-b as a
diagnostic or prognostic marker.
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